As an Executive-in-Residence at Summit Partners, Ken works alongside Summit’s healthcare & life sciences team to identify new investment opportunities and advise growth stage companies in the life sciences sector.
Ken brings 10 years of strategic and operating experience in the life sciences industry with deep experience driving business growth, building innovative new product pipelines and establishing strategic partnerships. Most recently, Ken was Vice President and Head of the Lab & Specialty Chemicals Business Unit of MilliporeSigma, the Life Science Division of Merck KgaA, where he successfully led the growth turnaround of the company’s product portfolio. In his time at MilliporeSigma, Ken held various leadership positions including roles in strategy, business development, strategic marketing and pricing. In addition, he helped lead the acquisition and integration of Sigma-Aldrich, one of the largest acquisitions in Merck KgaA history. Prior to MilliporeSigma, Ken was a management consultant with McKinsey & Co. where he advised pharmaceutical, medical device, diagnostic and private equity clients.
Ken holds a BS in chemistry, Phi Beta Kappa, from Stanford University and a PhD in neuroscience from Yale University.